Incyte to Present Oncology Data at ESMO 2026
Incyte says the data will include KRAS G12D and TGFβR2×PD-1 programs, informing ongoing registrational Phase 3 studies. An investor webcast is scheduled for Oct. 26.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Incyte to Present Oncology Data at ESMO Congress 2026
Incyte says it will present new data from its oncology portfolio at the ESMO Congress in Madrid, scheduled for October 23–27, 2026.
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Suppor
INCY Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Rapid oral presentations will highlight new Phase 1 data across Incyte's solid tumor portfolio Both INCB161734, an inves